Treatment(s) already received-Orchiectomy Posts on Medivizor
Navigation Menu

Treatment(s) already received-Orchiectomy Posts on Medivizor

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Evaluating the combination of sipuleucel-T with radium-223 in men with metastatic castration-resistant prostate cancer spread to the bone.

Posted by on May 3, 2021 in Prostate cancer | 0 comments

In a nutshell The study investigated the effectiveness of combining sipuleucel-T (Provenge) with radium-223 (Xofigo) therapy in men with castration-resistant prostate cancer (CRPC) that has spread to the bones. The key finding was that the combination therapy improved the survival rates of these patients.  Some background Prostate cancer often...

Read More

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Does a dose of 20 or 25 mg/m2 of cabazitaxel benefit patients with castration-resistant prostate cancer?

Posted by on Sep 8, 2020 in Prostate cancer | 0 comments

In a nutshell This study aimed to assess the effectiveness and safety of two doses of cabazitaxel  (Jevtana) (20 or 25 mg/m2) in the treatment of castration-resistant prostate cancer (CRPC) in the real-world practice. The study found that a lower dose of cabazitaxel benefited patients at high risk of having side...

Read More

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Does enzalutmide improve survival in nonmetastatic, castration-resistant prostate cancer?

Posted by on Jun 21, 2020 in Prostate cancer | 0 comments

In a nutshell The study assessed whether enzalutamide (Xtandi) plus androgen deprivation therapy (ADT) increased overall survival (OS) of patients with nonmetastatic, castration-resistant prostate cancer (CRPC). The study found improved survival in patients with CRPC treated with enzalutamide. Some background ADT is a type of hormonal therapy...

Read More

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Oncological safety of testosterone replacement therapy in prostate cancer survivors after definitive local therapy

Posted by on Aug 21, 2019 in Prostate cancer | 0 comments

In a nutshell This study aimed to evaluate the use of testosterone replacement therapy (TRT) in men who had definitive treatment for prostate cancer. The authors concluded that TRT was not associated with a higher risk of recurrence in these patients. Some background Prostate cancer (PCa) is commonly fueled by the sex hormone testosterone....

Read More

Looking for men with castration-resistant prostate cancer to try 177Lu-PSMA-617

Posted by on Feb 24, 2019 in Prostate cancer | 0 comments

In a nutshell This trial is looking at the effectiveness of 177Lu-PSMA-617 in the treatment of castration-resistant (tumor grows even with hormone therapy) prostate cancer. The main outcome to be measured is overall survival.  The details Prostate cancer is an uncontrolled growth of the cells which make up the prostate gland. Prostate...

Read More

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

PSA response after cabazitaxel treatment is associated with improved progression-free survival in men with metastatic castration-resistant prostate cancer.

Posted by on Jan 26, 2018 in Prostate cancer | 0 comments

In a nutshell This study aimed to examine the links between prostate specific antigen (PSA, a protein present in prostate cancer) and survival in patients with metastatic castration-resistant prostate cancer treated with cabazitaxel. This studty concluded that PSA response after cabazitaxel treatment is associated with improved...

Read More

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

An analysis of abiraterone plus prednisone for metastatic castration-resistant prostate cancer

Posted by on Nov 8, 2017 in Prostate cancer | 0 comments

In a nutshell This study aimed to determine which patients  benefited most from abiraterone acetate (Zytiga) and prednisone (Deltasone). This study found that overall survival was increased for all patient groups that received this combination.  Some background A main treatment option for prostate cancer is androgen deprivation...

Read More

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Radium 223-dichloride as a treatment for castration resistant prostate cancer

Posted by on Apr 3, 2017 in Prostate cancer | 0 comments

In a nutshell This study investigated how effective and safe radium 223 dichloride treatment was in patients with castration resistant prostate cancer (CRPC). It was concluded that radium 223 dichloride increased overall survival, reduced symptomatic skeletal events risk and was safe.  Some background Treatment to decrease the male hormones,...

Read More

Searching for men with metastatic castration-resistant prostate cancer to test new immunotherapy combination

Posted by on Mar 6, 2017 in Prostate cancer | 0 comments

In a nutshell This phase 2 trial aims to evaluate the benefit of adding tremelimumab to durvalumab, two new types of immunotherapy, for metastatic castration-resistant prostate cancer. The main outcome to be investigated is treatment response. The trial is recruiting in several locations in Canada.   The details Metastatic...

Read More

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Secondary hormone therapies: Should abiraterone or enzalutamide be administered first?

Posted by on Dec 19, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined whether abiraterone (Zytiga) or enzalutamide (Xtandi) should be administered first in the treatment of metastatic castration-resistant prostate cancer. Authors report preliminary evidence for reduced disease progression when administering abiraterone before enzalutamide compared to the reverse sequence. A significant...

Read More

What treatments are available for patients progressing after primary and secondary hormone therapy?

Posted by on Jul 29, 2016 in Prostate cancer | 0 comments

In a nutshell This study examined treatment patterns for metastatic castration-resistant prostate cancer (mCRPC) progressing after treatment with abiraterone acetate (Zytiga). Chemotherapy with docetaxel (Taxotere) was the most common subsequent therapy. Authors concluded that patients with mCRPC who progress after AA may still benefit from subsequent...

Read More